Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will present virtually at the 39th Annual J.P. Morgan Healthcare Conference. Norbert Riedel, Ph.D., chief executive officer, is scheduled to present on Thursday, January 14, 2021 at 9:10 a.m. Eastern Time.

A live webcast of the presentation will be available to view on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at https://ir.aptinyx.com and will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

Investor and Media Contact: Nick Smith Aptinyx Inc. ir@aptinyx.com or corporate@aptinyx.com 847-871-0377